Nov 30, 2017
By Jane Brown
If you suffer migraine headaches, you may want to discuss this news with your doctor.
A new wave of antibody-based treatments is showing promise for treatment of episodic and chronic migraine headaches.
One study tested Erenumab from Amgen and Novartis in about 900 people who averaged eight migraines a month. Nearly half had already tried other preventative medicines.
For six months, they were given monthly shots of a high dose of the drug, a low dose or a placebo. The number of days they suffered migraines each month dropped by three to four in the drug groups, and nearly two in the placebo group. And half of the patients on the higher dose saw their migraine days cut at least in half.
To learn about advertising opportunities with Zoomer Radio use the link below: